

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

August 20, 2024

REF: MDOL/CS-SE/2024-25/018

To,

Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 532637

Listing Department
**National Stock Exchange of India
Limited**
“Exchange Plaza”, 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: MANGALAM

SUBJECT: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR").

Dear Sir / Madam,

In terms of Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, We are pleased to announce that our Company is expanding its anti-malaria API portfolio with the introduction of Pyronaridine, having recently received prestigious pre-qualification from WHO Geneva. The World Health Organization has endorsed the Pyronaridine and Artesunate combination for malaria treatment, and we are proud to be the second company, following the innovator, to achieve this significant milestone. This development will position us at the forefront of anti-malaria API production globally and is expected to drive substantial growth and profitability for the Company.

Moreover, we are grateful for the support of the Bill and Melinda Gates Foundation (BMFG) in this project. We are currently collaborating with them for technical assistance to achieve

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

backward integration of Pyronaridine, which will enhance the cost-competitiveness of this API in the coming years.

The Medicine for Malaria Venture (MMV), headquartered in Geneva, Switzerland, is a non-profit organization dedicated to the development and support of innovative antimalarial therapies. MMV is actively engaged in advancing new treatments for malaria and is focused on optimizing combination therapies. The organization has endorsed the use of the pyronaridine-artesunate combination therapy as a recommended treatment for malaria. This combination leverages the synergistic effects of both drugs to enhance therapeutic efficacy and combat malaria more effectively.

Kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mangalam Drugs & Organics Limited**

Govardhan M. Dhoot

Managing Director

DIN : 01240086

Place : Mumbai